Cite
Turan GA, Eskicioglu F, Sivrikoz ON, et al. Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch Gynecol Obstet. 2016;293(3):691doi: 10.1007/s00404-016-4021-1.
Turan, G. A., Eskicioglu, F., Sivrikoz, O. N., Cengiz, H., Adakan, S., Gur, E. B., Tatar, S., Sahin, N., & Yilmaz, O. (2016). Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Archives of gynecology and obstetrics, 293(3), 691. https://doi.org/10.1007/s00404-016-4021-1
Turan, Guluzar Arzu, et al. "Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study." Archives of gynecology and obstetrics vol. 293,3 (2016): 691. doi: https://doi.org/10.1007/s00404-016-4021-1
Turan GA, Eskicioglu F, Sivrikoz ON, Cengiz H, Adakan S, Gur EB, Tatar S, Sahin N, Yilmaz O. Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch Gynecol Obstet. 2016 Mar;293(3):691. doi: 10.1007/s00404-016-4021-1. PMID: 26825729; PMCID: PMC4969927.
Copy
Download .nbib